Movement Disorders

Filter Your Results

 

News

 

Safety and Efficacy of Opicapone for Patients With Parkinson’s Disease

Tuesday, August 21, 2018—Safety and efficacy results for opicapone (Neurocrine Biosciences, San Diego, CA), an investigational treatment for end-of-dose motor symptoms, termed off-time, in patien…

Long-Term Safety and Efficacy of Valbenazine for Patients With Tardive Dyskinesia

Monday, August 20, 2018—Long-term results for valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA), a treatment for patients with tardive dyskinesia (TD), are being presented at the 2018 Wor…

Free Online Training for Professionals to Develop Exercise Programs for Those With Parkinson's Disease

Wednesday, August 15, 2018—An online training program has been launched by the Brain Grant Foundation to help professionals develop safe and effective exercise programming for people living with Parkins…

Funding Received for Phase 2 Trial of Xanomeline-Tropsium Chloride

Wednesday, August 08, 2018—A $42-million financing round has been completed and will be used to finance a phase 2 trial of xanomeline-tropsium chloride (KarXT; Karuna, Boston, MA) for treatment of perso…

Investigational Tau Modifier Receives Orphan Drug Status for Progressive Supranuclear Palsy

Wednesday, July 18, 2018—The Food and Drug Administration (FDA) has granted an orphan drug designation to ASN120290 (Asceneuron SA, Lausanne, Switzerland) for the treatment of progressive supranuclear…

IncobotulinumtoxinA Approved for Treatment of Excessive Drooling

Friday, July 13, 2018—The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for incobotulinumtoxin A (Xeomin; Merz, Raleigh, NC) for the treatmen…

New Dosing Formulation and Strength for Pimavanserin Approved

Friday, June 29, 2018—The Food and Drug Administration (FDA) has approved a new capsule dose formulation and a new tablet strength of pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA).…

New Monoclonal Antibodies Against Alpha-Synuclein Generated

Tuesday, June 26, 2018—ProMIS Neurosciences, Inc has announced that numerous antibodies against toxic oligomers of alpha-synuclein, implicated in Parkinson’s disease (PD) have begun the final …

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC